{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:40:42Z","timestamp":1789000842238,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00535-017-1407-1","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T09:18:19Z","timestamp":1510651099000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat"],"prefix":"10.1007","volume":"53","author":[{"given":"Hidekazu","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"issue":"3","key":"1407_CR1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.chom.2014.02.008","volume":"15","author":"M Hatakeyama","year":"2014","unstructured":"Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15(3):306\u201316 (Epub 2014\/03\/19).","journal-title":"Cell Host Microbe"},{"issue":"11","key":"1407_CR2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJMoa001999","volume":"345","author":"N Uemura","year":"2001","unstructured":"Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784\u20139 (Epub 2001\/09\/15).","journal-title":"N Engl J Med"},{"issue":"9","key":"1407_CR3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353\u201367 (Epub 2015\/07\/19).","journal-title":"Gut"},{"issue":"10","key":"1407_CR4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrgastro.2015.158","volume":"12","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Mori H. Helicobacter pylori: Helicobacter pylori gastritis-a novel distinct disease entity. Nat Rev Gastroenterol Hepatol. 2015;12(10):556\u20137 (Epub 2015\/09\/16).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"1407_CR5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000446301","volume":"1","author":"H Suzuki","year":"2016","unstructured":"Suzuki H, Mori H. Different pathophysiology of gastritis between East and West? An Asian perspective. Inflamm Intest Dis. 2016;1(3):123\u20138.","journal-title":"Inflamm Intest Dis"},{"issue":"5","key":"1407_CR6","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386 (Epub 2014\/09\/16).","journal-title":"Int J Cancer"},{"issue":"7","key":"1407_CR7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10654-010-9482-0","volume":"25","author":"MA Adamu","year":"2010","unstructured":"Adamu MA, Weck MN, Gao L, et al. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol. 2010;25(7):439\u201348 (Epub 2010\/06\/30).","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"1407_CR8","first-page":"835","volume":"11","author":"K Jaskiewicz","year":"1991","unstructured":"Jaskiewicz K, Louwrens HD. Chronic atrophic gastritis in a population at risk for gastric carcinoma. Anticancer Res. 1991;11(2):835\u20139 (Epub 1991\/03\/01).","journal-title":"Anticancer Res"},{"issue":"11","key":"1407_CR9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gut.2005.080358","volume":"55","author":"GM Naylor","year":"2006","unstructured":"Naylor GM, Gotoda T, Dixon M, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006;55(11):1545\u201352 (Epub 2006\/04\/11).","journal-title":"Gut"},{"issue":"9","key":"1407_CR10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1433","volume":"4","author":"M Hatakeyama","year":"2004","unstructured":"Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004;4(9):688\u201394 (Epub 2004\/09\/03).","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"1407_CR11","doi-asserted-by":"crossref","first-page":"14428","DOI":"10.1073\/pnas.222375399","volume":"99","author":"H Higashi","year":"2002","unstructured":"Higashi H, Tsutsumi R, Fujita A, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA. 2002;99(22):14428\u201333 (Epub 2002\/10\/23).","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1407_CR12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00535-003-1279-4","volume":"39","author":"T Azuma","year":"2004","unstructured":"Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol. 2004;39(2):97\u2013103 (Epub 2004\/04\/08).","journal-title":"J Gastroenterol"},{"issue":"5555","key":"1407_CR13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1126\/science.1067147","volume":"295","author":"H Higashi","year":"2002","unstructured":"Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science. 2002;295(5555):683\u20136 (Epub 2001\/12\/18).","journal-title":"Science"},{"issue":"3","key":"1407_CR14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hel.12193","volume":"20","author":"T Kamada","year":"2015","unstructured":"Kamada T, Haruma K, Ito M, et al. Time Trends in Helicobacter pylori Infection and Atrophic Gastritis Over 40 Years in Japan. Helicobacter. 2015;20(3):192\u20138 (Epub 2015\/01\/13).","journal-title":"Helicobacter"},{"key":"1407_CR15","doi-asserted-by":"publisher","unstructured":"Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5). https:\/\/doi.org\/10.1111\/hel.12415 .","DOI":"10.1111\/hel.12415"},{"issue":"9","key":"1407_CR16","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","volume":"53","author":"F Megraud","year":"2004","unstructured":"Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374\u201384 (Epub 2004\/08\/13).","journal-title":"Gut"},{"issue":"12","key":"1407_CR17","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/JCM.00740-07","volume":"45","author":"I Kobayashi","year":"2007","unstructured":"Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007;45(12):4006\u201310 (Epub 2007\/10\/19).","journal-title":"J Clin Microbiol"},{"issue":"6","key":"1407_CR18","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/AAC.00188-11","volume":"55","author":"T Nishizawa","year":"2011","unstructured":"Nishizawa T, Suzuki H, Tsugawa H, et al. Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication. Antimicrob Agents Chemother. 2011;55(6):3012\u20134 (Epub 2011\/04\/14).","journal-title":"Antimicrob Agents Chemother"},{"key":"1407_CR19","first-page":"45","volume":"17","author":"M Hashinaga","year":"2016","unstructured":"Hashinaga M, Okimoto T, Kodama M, et al. Drug resistance in Japan; the present status of Helicobacter pylori; the totaled results of the resistant strain survey in 2013 and 2014, wagakunini okeru yakuzaitaisei Helicobacter pylori no genjo\u20142013\u20132014 nendo taiseikin surveillance no syuukei houkoku. Jpn J Helicobacter Res. 2016;17:45\u20139.","journal-title":"Jpn J Helicobacter Res"},{"issue":"6","key":"1407_CR20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3343\/alm.2013.33.6.415","volume":"33","author":"B An","year":"2013","unstructured":"An B, Moon BS, Kim H, et al. Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. Ann. Lab Med. 2013;33(6):415\u20139 (Epub 2013\/11\/10).","journal-title":"Lab Med"},{"issue":"9","key":"1407_CR21","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3748\/wjg.v21.i9.2786","volume":"21","author":"YX Zhang","year":"2015","unstructured":"Zhang YX, Zhou LY, Song ZQ, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015;21(9):2786\u201392 (Epub 2015\/03\/12).","journal-title":"World J Gastroenterol"},{"issue":"7","key":"1407_CR22","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1440-1746.2009.05829.x","volume":"24","author":"WL Chang","year":"2009","unstructured":"Chang WL, Sheu BS, Cheng HC, et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol. 2009;24(7):1230\u20135 (Epub 2009\/05\/30).","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"1407_CR23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MCG.0b013e3182676e2b","volume":"47","author":"TT Binh","year":"2013","unstructured":"Binh TT, Shiota S, Nguyen LT, et al. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47(3):233\u20138 (Epub 2012\/10\/24).","journal-title":"J Clin Gastroenterol"},{"key":"1407_CR24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jgar.2015.09.009","volume":"5","author":"V Gehlot","year":"2016","unstructured":"Gehlot V, Mahant S, Mukhopadhyay AK, et al. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from patients in North India. J Glob Antimicrob Res. 2016;5:51\u20136 (Epub 2016\/07\/21).","journal-title":"J Glob Antimicrob Res"},{"issue":"3","key":"1407_CR25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1590\/0037-8682-0027-2015","volume":"48","author":"R Caliskan","year":"2015","unstructured":"Caliskan R, Tokman HB, Erzin Y, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop. 2015;48(3):278\u201384 (Epub 2015\/06\/25).","journal-title":"Rev Soc Bras Med Trop"},{"issue":"4","key":"1407_CR26","first-page":"363","volume":"21","author":"IM Saracino","year":"2012","unstructured":"Saracino IM, Zullo A, Holton J, et al. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. J Gastrointestin Liver Dis. 2012;21(4):363\u20135 (Epub 2012\/12\/21).","journal-title":"J Gastrointestin Liver Dis"},{"issue":"4","key":"1407_CR27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1523-5378.2012.00947.x","volume":"17","author":"J Molina-Infante","year":"2012","unstructured":"Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter. 2012;17(4):269\u201376 (Epub 2012\/07\/05).","journal-title":"Helicobacter"},{"issue":"4","key":"1407_CR28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fmb.10.25","volume":"5","author":"H Suzuki","year":"2010","unstructured":"Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol. 2010;5(4):639\u201348 (Epub 2010\/04\/01).","journal-title":"Future Microbiol"},{"issue":"4","key":"1407_CR29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diagmicrobio.2007.11.008","volume":"60","author":"L Boyanova","year":"2008","unstructured":"Boyanova L, Gergova G, Nikolov R, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12\u00a0years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008;60(4):409\u201315 (Epub 2008\/02\/06).","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"1407_CR30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1523-5378.2006.00414.x","volume":"11","author":"T Storskrubb","year":"2006","unstructured":"Storskrubb T, Aro P, Ronkainen J, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006;11(4):224\u201330 (Epub 2006\/08\/03).","journal-title":"Helicobacter"},{"issue":"3","key":"1407_CR31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000357862","volume":"32","author":"J Kupcinskas","year":"2014","unstructured":"Kupcinskas J, Leja M. Management of Helicobacter pylori-related diseases in the Baltic States. Dig Dis. 2014;32(3):295\u2013301 (Epub 2014\/04\/16).","journal-title":"Dig Dis"},{"issue":"6","key":"1407_CR32","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3201\/eid1006.030744","volume":"10","author":"WM Duck","year":"2004","unstructured":"Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004;10(6):1088\u201394 (Epub 2004\/06\/23).","journal-title":"Emerg Infect Dis."},{"issue":"7","key":"1407_CR33","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1128\/JCM.39.7.2677-2680.2001","volume":"39","author":"J Torres","year":"2001","unstructured":"Torres J, Camorlinga-Ponce M, Perez-Perez G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol. 2001;39(7):2677\u201380 (Epub 2001\/06\/28).","journal-title":"J Clin Microbiol"},{"issue":"4","key":"1407_CR34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1590\/S0004-28032011000400008","volume":"48","author":"JN Eisig","year":"2011","unstructured":"Eisig JN, Silva FM, Barbuti RC, et al. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011;48(4):261\u20134 (Epub 2011\/12\/08).","journal-title":"Arq Gastroenterol"},{"issue":"2","key":"1407_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3164\/jcbn.08-220R","volume":"44","author":"T Nishizawa","year":"2009","unstructured":"Nishizawa T, Suzuki H, Hibi T. Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication. J Clin Biochem Nutr. 2009;44(2):119\u201324 (Epub 2009\/03\/25).","journal-title":"J Clin Biochem Nutr"},{"issue":"Suppl 4","key":"1407_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/jgh.12796","volume":"29","author":"T Kawai","year":"2014","unstructured":"Kawai T, Takahashi S, Suzuki H, et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). J Gastroenterol Hepatol. 2014;29(Suppl 4):29\u201332 (Epub 2014\/12\/19).","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"1407_CR37","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/AAC.43.6.1497","volume":"43","author":"M Heep","year":"1999","unstructured":"Heep M, Beck D, Bayerdorffer E, et al. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999;43(6):1497\u20139 (Epub 1999\/05\/29).","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1407_CR38","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1128\/AAC.05437-11","volume":"55","author":"T Nishizawa","year":"2011","unstructured":"Nishizawa T, Suzuki H, Matsuzaki J, et al. Helicobacter pylori resistance to rifabutin in the last 7\u00a0years. Antimicrob Agents Chemother. 2011;55(11):5374\u20135 (Epub 2011\/09\/08).","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1407_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000191204","volume":"79","author":"S Suzuki","year":"2009","unstructured":"Suzuki S, Suzuki H, Nishizawa T, et al. Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori. Digestion. 2009;79(1):1\u20134 (Epub 2009\/01\/15).","journal-title":"Digestion"},{"issue":"1","key":"1407_CR40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report. Gut. 2017;66(1):6\u201330 (Epub 2016\/11\/02).","journal-title":"Gut"},{"issue":"9","key":"1407_CR41","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439\u201346 (Epub 2016\/03\/05).","journal-title":"Gut"},{"issue":"30","key":"1407_CR42","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.3748\/wjg.v20.i30.10338","volume":"20","author":"J Molina-Infante","year":"2014","unstructured":"Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20(30):10338\u201347 (Epub 2014\/08\/19).","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1407_CR43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmi.2016.12.032","volume":"23","author":"L Wang","year":"2017","unstructured":"Wang L, Lin Z, Chen S, et al. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. Clin Microbiol Infect. 2017;23(6):391\u20135 (Epub 2017\/01\/13).","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1407_CR44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clinre.2015.12.012","volume":"40","author":"N Muller","year":"2016","unstructured":"Muller N, Amiot A, Le Thuaut A, et al. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clin Res Hepatol Gastroenterol. 2016;40(4):517\u201324 (Epub 2016\/02\/07).","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"6","key":"1407_CR45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MCG.0000000000000165","volume":"49","author":"T Nishizawa","year":"2015","unstructured":"Nishizawa T, Maekawa T, Watanabe N, et al. Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J Clin Gastroenterol. 2015;49(6):468\u201371 (Epub 2014\/06\/13).","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"1407_CR46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/hel.12063","volume":"18","author":"D Asaoka","year":"2013","unstructured":"Asaoka D, Nagahara A, Matsuhisa T, et al. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. Helicobacter. 2013;18(6):468\u201372 (Epub 2013\/06\/19).","journal-title":"Helicobacter"},{"issue":"8","key":"1407_CR47","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ejim.2014.08.010","volume":"25","author":"A Zullo","year":"2014","unstructured":"Zullo A, Esposito G, Ridola L, et al. Prevalence of lesions detected at upper endoscopy: an Italian survey. Eur J Intern Med. 2014;25(8):772\u20136 (Epub 2014\/09\/24).","journal-title":"Eur J Intern Med"},{"issue":"10","key":"1407_CR48","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1365-2036.2006.03149.x","volume":"24","author":"JP Gisbert","year":"2006","unstructured":"Gisbert JP, Gisbert JL, Marcos S, et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24(10):1469\u201374 (Epub 2006\/10\/13).","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1407_CR49","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00535-012-0731-8","volume":"48","author":"K Murakami","year":"2013","unstructured":"Murakami K, Furuta T, Ando T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013;48(10):1128\u201335 (Epub 2013\/01\/12).","journal-title":"J Gastroenterol"},{"key":"1407_CR50","first-page":"631501","volume":"2014","author":"K Okimoto","year":"2014","unstructured":"Okimoto K, Arai M, Saito K, et al. Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies. Int Sch Res Not. 2014;2014:631501 (Epub 2014\/01\/01).","journal-title":"Int Sch Res Not"},{"issue":"21","key":"1407_CR51","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.3748\/wjg.v21.i21.6698","volume":"21","author":"OA Paoluzi","year":"2015","unstructured":"Paoluzi OA, Del Vecchio Blanco G, Visconti E, et al. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol. 2015;21(21):6698\u2013705 (Epub 2015\/06\/16).","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1407_CR52","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1128\/AAC.01131-10","volume":"55","author":"JM Liou","year":"2011","unstructured":"Liou JM, Chang CY, Sheng WH, et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother. 2011;55(3):1123\u20139 (Epub 2010\/12\/30).","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1407_CR53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.dld.2007.06.016","volume":"39","author":"F Perna","year":"2007","unstructured":"Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39(11):1001\u20135 (Epub 2007\/09\/25).","journal-title":"Dig Liver Dis"},{"issue":"3","key":"1407_CR54","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.05941-11","volume":"56","author":"J Matsuzaki","year":"2012","unstructured":"Matsuzaki J, Suzuki H, Nishizawa T, et al. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrob Agents Chemother. 2012;56(3):1643\u20135 (Epub 2011\/12\/29).","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1407_CR55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/hel.12286","volume":"21","author":"H Mori","year":"2016","unstructured":"Mori H, Suzuki H, Matsuzaki J, et al. Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for Helicobacter pylori strains containing the gyrA mutation. Helicobacter. 2016;21(4):286\u201394 (Epub 2015\/11\/28).","journal-title":"Helicobacter"},{"issue":"4","key":"1407_CR56","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/AAC.00049-09","volume":"53","author":"H Suzuki","year":"2009","unstructured":"Suzuki H, Nishizawa T, Muraoka H, et al. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother. 2009;53(4):1720\u20131 (Epub 2009\/02\/04).","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"1407_CR57","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1111\/j.1440-1746.2010.06245.x","volume":"25","author":"J Matsuzaki","year":"2010","unstructured":"Matsuzaki J, Suzuki H, Tsugawa H, et al. Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy. J Gastroenterol Hepatol. 2010;25(Suppl 1):S7\u201310 (Epub 2010\/07\/14).","journal-title":"J Gastroenterol Hepatol"},{"issue":"35","key":"1407_CR58","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.3748\/wjg.14.5385","volume":"14","author":"JP Gisbert","year":"2008","unstructured":"Gisbert JP. \u201cRescue\u201d regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14(35):5385\u2013402 (Epub 2008\/09\/23).","journal-title":"World J Gastroenterol"},{"key":"1407_CR59","doi-asserted-by":"publisher","DOI":"10.1177\/2050640617737215","author":"H Mori","year":"2017","unstructured":"Mori H, Suzuki H, Matsuzaki J, et al. Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens. United Eur Gastroenterol J. 2017. https:\/\/doi.org\/10.1177\/2050640617737215 .","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"1407_CR60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2036.2006.02993.x","volume":"24","author":"S Miehlke","year":"2006","unstructured":"Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006;24(2):395\u2013403 (Epub 2006\/07\/18).","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"1407_CR61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2012.05053.x","volume":"35","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35(8):941\u20137 (Epub 2012\/03\/01).","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1407_CR62","first-page":"58","volume":"96","author":"F Perri","year":"2001","unstructured":"Perri F, Festa V, Clemente R, et al. Randomized study of two \u201crescue\u201d therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001;96(1):58\u201362 (Epub 2001\/02\/24).","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1407_CR63","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/2050640615618043","volume":"4","author":"H Mori","year":"2016","unstructured":"Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United Eur Gastroenterol J. 2016;4(3):380\u20137 (Epub 2016\/07\/13).","journal-title":"United Eur Gastroenterol J."},{"issue":"5","key":"1407_CR64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/hel.12296","volume":"21","author":"AF Ciccaglione","year":"2016","unstructured":"Ciccaglione AF, Tavani R, Grossi L, et al. Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies. Helicobacter. 2016;21(5):375\u201381 (Epub 2016\/01\/26).","journal-title":"Helicobacter"},{"issue":"2","key":"1407_CR65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","volume":"35","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35(2):209\u201321 (Epub 2011\/12\/02).","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1407_CR66","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/hel.12147","volume":"19","author":"HC Lim","year":"2014","unstructured":"Lim HC, Lee YJ, An B, et al. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19(6):455\u201361 (Epub 2014\/09\/19).","journal-title":"Helicobacter"},{"issue":"21","key":"1407_CR67","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3748\/wjg.v18.i21.2735","volume":"18","author":"T Nishizawa","year":"2012","unstructured":"Nishizawa T, Suzuki H, Maekawa T, et al. Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction. World J Gastroenterol. 2012;18(21):2735\u20138 (Epub 2012\/06\/13).","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1407_CR68","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3164\/jcbn.16-86","volume":"60","author":"T Nishizawa","year":"2017","unstructured":"Nishizawa T, Suzuki H, Fujimoto A, et al. Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. J Clin Biochem Nutr. 2017;60(3):208\u201310 (Epub 2017\/06\/07).","journal-title":"J Clin Biochem Nutr"},{"issue":"9636","key":"1407_CR69","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(08)61159-9","volume":"372","author":"K Fukase","year":"2008","unstructured":"Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392\u20137 (Epub 2008\/08\/05).","journal-title":"Lancet"},{"issue":"4","key":"1407_CR70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/hel.12146","volume":"19","author":"SB Yoon","year":"2014","unstructured":"Yoon SB, Park JM, Lim CH, et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014;19(4):243\u20138 (Epub 2014\/07\/25).","journal-title":"Helicobacter."},{"key":"1407_CR71","doi-asserted-by":"crossref","first-page":"g3174","DOI":"10.1136\/bmj.g3174","volume":"348","author":"AC Ford","year":"2014","unstructured":"Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174 (Epub 2014\/05\/23).","journal-title":"BMJ"},{"issue":"3","key":"1407_CR72","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00535-010-0347-9","volume":"46","author":"S Take","year":"2011","unstructured":"Take S, Mizuno M, Ishiki K, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011;46(3):318\u201324 (Epub 2010\/11\/26).","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-017-1407-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1407-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T06:25:40Z","timestamp":1659853540000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-017-1407-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1007\/s00535-017-1407-1","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}